Alkermes plc (NASDAQ:ALKS) Shares Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. grew its holdings in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 426.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,862 shares of the company's stock after buying an additional 54,172 shares during the period. Alkermes accounts for about 0.3% of Fox Run Management L.L.C.'s holdings, making the stock its 21st largest holding. Fox Run Management L.L.C.'s holdings in Alkermes were worth $1,923,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Loomis Sayles & Co. L P increased its position in Alkermes by 365.5% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company's stock valued at $52,704,000 after acquiring an additional 1,478,422 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in shares of Alkermes during the third quarter worth $16,126,000. Raymond James Financial Inc. purchased a new position in Alkermes in the 4th quarter valued at $12,293,000. C WorldWide Group Holding A S purchased a new position in Alkermes during the 4th quarter worth $7,190,000. Finally, Barclays PLC raised its position in Alkermes by 108.8% during the 3rd quarter. Barclays PLC now owns 423,931 shares of the company's stock worth $11,867,000 after buying an additional 220,893 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a "neutral" rating and set a $46.00 price target on shares of Alkermes in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Alkermes in a research note on Tuesday, February 11th. They set a "buy" rating and a $40.00 target price for the company. The Goldman Sachs Group lifted their price target on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, February 14th. UBS Group upgraded Alkermes from a "sell" rating to a "neutral" rating and increased their price objective for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Alkermes presently has an average rating of "Moderate Buy" and a consensus target price of $38.46.

Remove Ads

Alkermes Price Performance

NASDAQ:ALKS traded up $0.00 during trading hours on Tuesday, reaching $34.79. 205,136 shares of the company traded hands, compared to its average volume of 1,695,442. The firm's 50-day moving average is $33.10 and its 200-day moving average is $30.12. The stock has a market cap of $5.66 billion, a P/E ratio of 16.05, a P/E/G ratio of 2.20 and a beta of 0.62. Alkermes plc has a 1-year low of $22.90 and a 1-year high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. As a group, research analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 100,918 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now owns 44,290 shares of the company's stock, valued at approximately $1,419,494.50. This represents a 69.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.89% of the stock is owned by company insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.